Gupta Pramod K, Jaiswal Anil K, Asthana Shalini, Teja B Venkatesh, Shukla Prashant, Shukla Minakshi, Sagar Neeti, Dube Anuradha, Rath Srikanta K, Mishra Prabhat R
Pharmaceutics Division, Council of Scientific and Industrial Research-Central Drug Research Institute, Lucknow, India.
Parasitology Division, Council of Scientific and Industrial Research-Central Drug Research Institute, Lucknow, India.
Br J Pharmacol. 2015 Jul;172(14):3596-610. doi: 10.1111/bph.13149. Epub 2015 May 19.
The aim of this study was to devise a nanoemulsified carrier system (CopNEC) to improve the oral delivery of amphotericin B (AmB) by increasing its oral bioavailability and synergistically enhance its antileishmanial activity with copaiba oil (Cop).
The AmB encapsulated NEC (CopNEC-AmB) comprised of Cop, d-α-tocopheryl polyethylene glycol 1000 succinate and phosphatidylcholine was prepared by high-pressure homogenization method. Stability study of CopNEC-AmB was carried out in simulated gastric fluid and simulated intestinal fluid. The CopNEC-AmB and plain AmB were compared as regards their in vitro antileishmanial activity, pharmacokinetics, organ distribution and toxicity.
The optimal CopNEC-AmB had a small globule size, low polydispersity index, high ζ potential and encapsulation efficiency. The high resolution transmission electron microscopy illustrated spherical particle geometry with homogeny in their sizes. The optimal CopNEC-AmB was found to be stable in gastrointestinal fluids showing insignificant changes in globule size and encapsulation efficiency. The AUC0-48 value of CopNEC-AmB in rats was significantly improved showing 7.2-fold higher oral bioavailability than free drug. The in vitro antileishmanial activity of CopNEC-AmB was significantly higher than that of the free drug as Cop synergistically enhanced the antileishmanial effect of AmB by causing drastic changes in the morphology of Leishmania parasite and rupturing its plasma membrane. The CopNEC-AmB showed significantly less haemolytic toxicity and cytotoxicity and did not change the histopathology of kidney tissues as compared with AmB alone.
This prototype CopNEC formulation showed improved bioavailability and had a non-toxic synergistic effect on the antileishmanial activity of AmB.
本研究的目的是设计一种纳米乳化载体系统(CopNEC),通过提高两性霉素B(AmB)的口服生物利用度来改善其口服给药,并与巴西香脂油(Cop)协同增强其抗利什曼原虫活性。
采用高压均质法制备了由Cop、聚乙二醇1000维生素E琥珀酸酯和磷脂酰胆碱组成的AmB包封纳米乳(CopNEC-AmB)。在模拟胃液和模拟肠液中对CopNEC-AmB进行稳定性研究。比较了CopNEC-AmB和普通AmB在体外抗利什曼原虫活性、药代动力学、器官分布和毒性方面的差异。
最佳的CopNEC-AmB具有小球径、低多分散指数、高ζ电位和包封率。高分辨率透射电子显微镜显示其为球形颗粒,大小均匀。发现最佳的CopNEC-AmB在胃肠液中稳定,其粒径和包封率变化不显著。CopNEC-AmB在大鼠体内的AUC0-48值显著提高,口服生物利用度比游离药物高7.2倍。CopNEC-AmB的体外抗利什曼原虫活性显著高于游离药物,因为Cop通过引起利什曼原虫形态的剧烈变化并破坏其质膜,协同增强了AmB的抗利什曼原虫作用。与单独使用AmB相比,CopNEC-AmB的溶血毒性和细胞毒性显著降低,且未改变肾组织的组织病理学。
这种CopNEC原型制剂显示出提高的生物利用度,并且对AmB的抗利什曼原虫活性具有无毒协同作用。